Home›Nipocalimab

Nipocalimab

Also known as: Imaavy

Route: Intravenous

3 interactions on record

Nipocalimab has 3 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Drugs That Prolong The Qt Interval, Immunoglobulin Products, Monoclonal Antibodies. Patients taking Nipocalimab should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Moderate: 3

Moderate (3)

Nipocalimab + Drugs That Prolong The Qt Interval— Concomitant use may lower systemic exposures and reduce effectiveness. Closely monitor for reduced effectiveness; consid…
Nipocalimab + Immunoglobulin Products— Concomitant use may lower systemic exposures and reduce effectiveness of immunoglobulin products. Closely monitor for re…
Nipocalimab + Monoclonal Antibodies— Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for redu…

Nipocalimab + Drugs That Prolong The Qt Interval🟡Moderate

Concomitant use may lower systemic exposures and reduce effectiveness. Closely monitor for reduced effectiveness; consider discontinuing IMAAVY.

Nipocalimab + Immunoglobulin Products🟡Moderate

Concomitant use may lower systemic exposures and reduce effectiveness of immunoglobulin products. Closely monitor for reduced effectiveness.

Nipocalimab + Monoclonal Antibodies🟡Moderate

Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for reduced effectiveness.

Contraindications

4 CONTRAINDICATIONS IMAAVY is contraindicated in patients with a history of serious hypersensitivity reaction to nipocalimab or any of the excipients in IMAAVY. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.2) ] . IMAAVY is contraindicated in patients with a history of serious hypersensitivity reaction to nipocalimab or to any of the excipients in IMAAVY. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary There are limited data on the use of IMAAVY in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There was no evidence of direct adverse effects on fetal development following administration of nipocalimab-aahu to pregnant monkeys; however, adverse effects on the placenta were associated with fetal loss at both doses tested (see Data ) . The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background rate of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. There is a pregnancy safety study for IMAAVY. If IMAAVY is administered during pregnancy, or if a patient becomes pregnant while receiving IMAAVY, healthcare providers should report IMAAVY exposure by contacting Janssen at 1-800-526-7736 or www.IMAAVY.com Clinical Considerations Fetal/Neonatal Adverse Reactions Monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Because IMAAVY reduces maternal serum IgG concentration and impedes placental IgG transfer to the fetus, passive immunity in the infant may be reduced for 6 months or more; therefore: Monitor for the development of serious infection. Effectiveness of vaccines may be reduced. Consider the risks and benefits prior to administering live vaccines to infants exposed to IMAAVY in utero . Animal Data Intravenous administration of nipocalimab-aahu (0, 100, or 300 mg/kg) to pregnant monkeys weekly from the end of organogenesis (gestation day 45) through parturition resulted in placental ischemia, associated with fetal loss and decreased levels of IgG in the offspring at both doses tested. IgG levels in offspring retu

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.